Showing results (51-60 of 89) with videos related to
Sort By:
Pageof 9
International Journal of Cancer|November 1, 2015
Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantationRosaely Casalegno-Garduño, Anita Schmitt, Alf Spitschak, et al.Journal of Clinical Medicine|February 10, 2019
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)Susanne Hofmann, Maria-Luisa Schubert, Lei Wang, et al.Blood Advances|September 8, 2021
Fatal late-onset CAR T-cell-mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphomaSusanne Jung, Jochen Greiner, Stephanie von Harsdorf, et al.Experimental Hematology|July 16, 2008
Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigensFei Fei, Yingzhe Yu, Anita Schmitt, et al.Cancer Immunology, Immunotherapy : CII|September 30, 2006
Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitroJinfei Chen, Anita Schmitt, Baoan Chen, et al.Oncology Research and Treatment|June 17, 2020
A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer SocietyLothar Bergmann, Viktor Grünwald, Luise Maute, et al.British Journal of Haematology|January 16, 2007
Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapseMark Ringhoffer, Stephanie von Harsdorf, Michael Schmitt, et al.Blood|August 26, 2006
Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approachesJochen Greiner, Michael Schmitt, Li Li, et al.Journal of Neuro-Oncology|May 16, 2020
Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with ("pseudo-randomized") treatment allocation by the health insurance providerSusanne Hofmann, Manuel Alexander Schmidt, Thomas Weissmann, et al.Nature|March 3, 2016
Positron annihilation signatures associated with the outburst of the microquasar V404 CygniThomas Siegert, Roland Diehl, Jochen Greiner, et al.Pageof 9